Monthly Stock Report: DexCom, Inc. (DXCM)
Publication Date: September 22, 2024
Company Overview
DexCom, Inc. (DXCM) is a San Diego-based healthcare company that stands at the forefront of medical device innovation. Established in 1999, DexCom specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems, with notable products like the Dexcom G6 and G7 catering to diabetes management. The company is not only committed to enhancing diabetes care with its innovative solutions but also empowers patients and healthcare providers through tools like Dexcom Share for remote monitoring. Ahead of the FDA review for new products targeting type 2 diabetes patients, DexCom showcases its dedication to advancing healthcare technology and presents unique investment opportunities within a rapidly evolving market space.
Financial Performance and Market Sentiment
With approximately $3.93 billion in total revenue, DexCom demonstrates impressive financial performance and robust growth potential. Analysts hold an overwhelmingly positive sentiment, issuing a “buy” rating for the stock. The current stock price is $70.43, significantly below the target high price of $130.00, indicating a promising upside. Furthermore, with a target mean price set at $97.25, analysts anticipate substantial upward movement in the stock. The company has 400,727,008 outstanding shares, with a short interest of 7,334,153 shares, representing only 2.07% of the float, signaling positive market sentiment towards Dexter’s future performance.
Stock Valuation Insights
Despite being below both its fifty-day average of $79.08 and its fifty-two week high of $142.00, DexCom’s stock price reflects excellent potential for growth. The fifty-two week low of $62.34 indicates some resilience, as the current stock price remains above this level. Analysts report a balanced outlook with a median target of $95.85, encouraging potential investors to consider capitalizing on this opportunity. The recommendation mean of 1.8 from 23 analysts underscores a clear consensus on the stock’s long-term value proposition, making DexCom an attractive consideration for those looking to invest in healthcare technology advancements.
| Metric | Value |
|---|---|
| Market Cap | $28.2b |
| Total Debt | $2.6b |
| Total Cash | $3.1b |
| Shares Outstanding | 400.7m |
| Float Shares | 397.7m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.